A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update Meeting Abstract
| Authors: | Ahn, M. J.; Cho, B.; Kim, T. M.; Han, J. Y.; Kim, C.; Shim, B.; Drilon, A.; Blumenschein, G.; Villaruz, L.; Gray, J. E.; Pujol, J. L.; Lena, H.; Moro-Sibilot, D.; Perez, J.; Modi, D. A.; Park, J. S.; Patel, S.; Li, S.; Kim, E.; Magnan, H. |
| Abstract Title: | A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update |
| Meeting Title: | ESMO Asia Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2024 Dec 6-8 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-12-01 |
| Start Page: | S1673 |
| End Page: | S1674 |
| Language: | English |
| ACCESSION: | WOS:001386524200059 |
| DOI: | 10.1016/j.annonc.2024.10.754 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 721TiP -- Source: Wos |
